当前位置: 首页 >> 检索结果
共有 2156 条符合本次的查询结果, 用时 2.836755 秒

1901. COUNTERPOINT: Should Asymptomatic OSA Be Treated in Patients With Significant Cardiovascular Disease? No.

作者: Naresh M Punjabi.;Daniel J Gottlieb.
来源: Chest. 2022年161卷3期607-611页

1902. POINT: Should Asymptomatic OSA Be Treated in Patients With Significant Cardiovascular Disease? Yes.

作者: Reena Mehra.;Cinthya Pena Orbea.
来源: Chest. 2022年161卷3期605-607页

1903. Tempering Steel With Fire: A Winning Combination for Patients With Early Stage Lung Cancer.

作者: Pamela Samson.;Clifford Robinson.
来源: Chest. 2022年161卷3期603-604页

1904. An Important Window Into Respiratory Muscle Decline.

作者: Oscar Henry Mayer.
来源: Chest. 2022年161卷3期601-602页

1905. Challenging the Evidence for Pulmonary Rehabilitation in Pulmonary Fibrosis: Is Good, Enough?

作者: Christian R Osadnik.
来源: Chest. 2022年161卷3期599-600页

1906. Walk a Mile in My Shoes: Assessing the Importance of Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis.

作者: Michael C Sklar.;Domenico L Grieco.
来源: Chest. 2022年161卷3期597-598页

1907. Spirometry: The Indefinite Search for Gold.

作者: E F M Wouters.;R Breyer-Kohansal.
来源: Chest. 2022年161卷3期593-594页

1908. Should We Start With Navigation or Endobronchial Ultrasound Bronchoscopy?: Insights From Monte Carlo Simulations.

作者: Michael N Kammer.;Brent E Heideman.;Fabien Maldonado.
来源: Chest. 2022年162卷1期265-268页

1909. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma.

作者: Mark H Moss.;Njira L Lugogo.;Mario Castro.;Nicola A Hanania.;Andrea Ludwig-Sengpiel.;Dinesh Saralaya.;Rafal Dobek.;Iñigo Ojanguren.;Ivan Vyshnyvetskyy.;Jean-Marie Bruey.;Robin Osterhout.;Cindy-Ann Tompkins.;Karen Dittrich.;Kartik Raghupathi.;Hector Ortega.; .
来源: Chest. 2022年162卷2期297-308页
Prostaglandin D2 receptor 2 (DP2) antagonists inhibit prostaglandin D2-induced effects, including recruitment and activation of cells driving asthma pathogenesis. However, challenges identifying target population and end points persist.

1910. BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.

作者: Breanne E McCarthy.;Robyn L McClelland.;Dina H Appleby.;Jude S Moutchia.;Jasleen K Minhas.;Jeff Min.;Jeremy A Mazurek.;K Akaya Smith.;Jason S Fritz.;Steven C Pugliese.;Ryan J Urbanowicz.;John H Holmes.;Harold I Palevsky.;Steven M Kawut.;Nadine Al-Naamani.
来源: Chest. 2022年162卷2期436-447页
Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an "obesity paradox" in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies.

1911. Pulmonary Langerhans Cell Histiocytosis and Lymphangioleiomyomatosis Have Circulating Cells With Loss of Heterozygosity of the TSC2 Gene.

作者: Davide Elia.;Olga Torre.;Chiara Vasco.;Jens Geginat.;Sergio Abrignani.;Elisabetta Bulgheroni.;Elena Carelli.;Roberto Cassandro.;Gustavo Pacheco-Rodriguez.;Wendy K Steagall.;Joel Moss.;Sergio Harari.
来源: Chest. 2022年162卷2期385-393页
Lymphangioleiomyomatosis (LAM) and pulmonary Langerhans cell histiocytosis (PLCH) are cystic lung diseases in which a neoplastic cell is thought to be responsible for disease pathogenesis. The neoplastic LAM cell has mutations in the TSC genes, TSC1 or TSC2, whereas the neoplastic PLCH cell may have mutations in several genes (eg, BRAF, NRAS, MAP2K1). These mutations are not specific for PLCH and have been described in multiple cancers. TSC1 or TSC2 mutations and loss of heterozygosity (LOH) have also been described in cancers.

1912. Invasive Procedures and Associated Complications After Initial Lung Cancer Screening in a National Cohort of Veterans.

作者: Eduardo R Núñez.;Tanner J Caverly.;Sanqian Zhang.;Mark E Glickman.;Shirley X Qian.;Jacqueline H Boudreau.;Donald R Miller.;Renda Soylemez Wiener.
来源: Chest. 2022年162卷2期475-484页
Little is known about rates of invasive procedures and associated complications after lung cancer screening (LCS) in nontrial settings.

1913. Mechanical Ventilator Liberation of Patients With COVID-19 in Long-term Acute Care Hospital.

作者: Tamas Dolinay.;Dale Jun.;Lucia Chen.;Jeffrey Gornbein.
来源: Chest. 2022年161卷6期1517-1525页
Mechanical ventilation (MV) via tracheostomy is performed commonly for patients who are in long-term acute care hospitals (LTACHs) after respiratory failure. However, the outcome of MV in COVID-19-associated respiratory failure in LTACHs is not known.

1914. Management of Life-Threatening Asthma: Severe Asthma Series.

作者: Orlando Garner.;James Scott Ramey.;Nicola A Hanania.
来源: Chest. 2022年162卷4期747-756页
Asthma exacerbations can be life-threatening, with 25,000 to 50,000 such patients per year requiring admission to an ICU in the United States. Appropriate triage of life-threatening asthma is dependent on both static assessment of airway function and dynamic assessment of response to therapy. Treatment strategies focus on achieving effective bronchodilation with inhaled β2-agonists, muscarinic antagonists, and magnesium sulphate while reducing inflammation with systemic corticosteroids. Correction of hypoxemia and hypercapnia, a key in managing life-threatening asthma, occasionally requires the incorporation of noninvasive mechanical ventilation to decrease the work of breathing. Endotracheal intubation and mechanical ventilation should not be delayed if clinical improvement is not achieved with conservative therapies. However, mechanical ventilation in these patients often requires controlled hypoventilation, adequate sedation, and occasional use of muscle relaxation to avoid dynamic hyperinflation, which can result in barotrauma or volutrauma. Sedation with ketamine or propofol is preferred because of their potential bronchodilation properties. In this review, we outline strategies for the assessment and management of patients with acute life-threatening asthma focusing on those requiring admission to the ICU.

1915. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.

作者: Lawrence D Sher.;Michael E Wechsler.;Klaus F Rabe.;Jorge F Maspero.;Nadia Daizadeh.;Xuezhou Mao.;Benjamin Ortiz.;Leda P Mannent.;Elizabeth Laws.;Marcella Ruddy.;Nami Pandit-Abid.;Juby A Jacob-Nara.;Rebecca Gall.;Paul J Rowe.;Yamo Deniz.;David J Lederer.;Megan Hardin.
来源: Chest. 2022年162卷1期46-55页
Many patients with severe asthma require chronic corticosteroid treatment to maintain asthma control.

1916. Frailty in Patients With Lung Cancer: A Systematic Review and Meta-Analysis.

作者: Klara Komici.;Leonardo Bencivenga.;Neal Navani.;Vito D'Agnano.;Germano Guerra.;Andrea Bianco.;Giuseppe Rengo.;Fabio Perrotta.
来源: Chest. 2022年162卷2期485-497页
Previous studies regarding the prevalence of frailty in patients with lung cancer and mortality in frail patients with lung cancer are inconsistent and require clarification.

1917. Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial.

作者: Jagat Jeevan Ghimire.;Kana Ram Jat.;Jhuma Sankar.;Rakesh Lodha.;Venkat K Iyer.;Hitender Gautam.;Seema Sood.;S K Kabra.
来源: Chest. 2022年161卷6期1456-1464页
Azithromycin has immunomodulatory actions, and its beneficial effects have been demonstrated in asthmatic adults. Data on children are limited.

1918. Comparison of Full-Dose vs Moderate-Dose Systemic Thrombolysis for the Treatment of Patients With Acute Pulmonary Embolism.

作者: Ana Jaureguízar.;Cassius Iyad Ochoa Chaar.;Alfonso Muriel.;Jerónimo Ramón Vela Moreno.;Ido Weinberg.;Antonella Tufano.;José F Varona.;Behnood Bikdeli.;David Jiménez.;Manuel Monreal.; .
来源: Chest. 2022年162卷2期448-451页

1919. Temporal Trends in Rural vs Urban Sepsis-Related Mortality in the United States, 2010-2019.

作者: Lavi Oud.;John Garza.
来源: Chest. 2022年162卷1期132-135页

1920. Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.

作者: Franck F Rahaghi.;Nicholas A Kolaitis.;Ayodeji Adegunsoye.;Joao A de Andrade.;Kevin R Flaherty.;Lisa H Lancaster.;Joyce S Lee.;Deborah J Levine.;Ioana R Preston.;Zeenat Safdar.;Rajan Saggar.;Sandeep Sahay.;Mary Beth Scholand.;Oksana A Shlobin.;David A Zisman.;Steven D Nathan.
来源: Chest. 2022年162卷1期145-155页
Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD) and is associated with worse outcomes and increased mortality. Evaluation of PH is recommended in lung transplant candidates, but there are currently no standardized screening approaches. Trials have identified therapies that are effective in this setting, providing another rationale to routinely screen patients with ILD for PH.
共有 2156 条符合本次的查询结果, 用时 2.836755 秒